Menu Search
Equities

Ultragenyx Pharmaceutical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0LIF:LSE

Ultragenyx Pharmaceutical Inc

Actions
  • Price (USD)24.45
  • Today's Change0.568 / 2.38%
  • Shares traded324.00
  • 1 Year change-45.38%
  • Beta0.1545
Data delayed at least 20 minutes, as of Feb 10 2026 18:20 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

  • Revenue in USD (TTM)630.60m
  • Net income in USD-579.83m
  • Incorporated2011
  • Employees1.29k
  • Location
    Ultragenyx Pharmaceutical Inc60 Leveroni CtNOVATO 94949-5746United StatesUSA
  • Phone+1 (415) 483-8800
  • Fax+1 (415) 483-8810
  • Websitehttps://www.ultragenyx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.